Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | ACP1 | P24666 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 6/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31197371 | 0.94 | S1PR2 (0.57) | S1PR2LMNASMN1; SMN2NPSR1CYP1A2 | |
| SCHEMBL10589295 | 0.94 | S1PR2 (0.57) | S1PR2LMNASMN1; SMN2NPSR1CYP1A2 | |
| SCHEMBL9602243 | 0.94 | S1PR2 (0.57) | S1PR2LMNASMN1; SMN2NPSR1CYP1A2 | |
| SCHEMBL18843434 | 0.91 | APP (0.50) | S1PR2LMNASMN1; SMN2NPSR1CYP1A2 | |
| SCHEMBL6096807 | 0.89 | HTR1A (0.51) | HRH3SLC2A1POLBRAD52 | |
| SCHEMBL7218710 | 0.87 | POLB (0.45) | LMNAHRH3SLC2A1CACNA2D1POLB | |
| SCHEMBL6787115 | 0.85 | HRH3 (0.45) | HRH3SLC2A1CACNA2D1POLBRAD52 | |
| SCHEMBL10728537 | 0.85 | POLB (0.63) | LMNASMN1; SMN2HRH3SLC2A1POLB | |
| SCHEMBL4336578 | 0.85 | POLB (0.44) | LMNAHRH3SLC2A1CACNA2D1POLB | |
| SCHEMBL9837697 | 0.84 | MEN1 (0.42) | CYP1A2HRH3KMT2AMEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| EP-1701955-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005123079-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005066170-A1 | ARYLALKENYL AND ARYLALKYNYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-4698348-A | 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents | RIKER LABORATORIES, INC. (US) | 1987-10-06 | — | — | US | disclosed |
| US-4689338-A | 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use | RIKER LABORATORIES, INC. (US) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | IL2, EIF2AK2, IL4 | S1PR2 3970/4885LMNA 3978/4885SMN1; SMN2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.